Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis

Walther, A.; Houlston, H.; Tomlinson, I.
July 2008
Gut;Jul2008, Vol. 57 Issue 7, p941
Academic Journal
Background: Several studies have suggested that microsatellite instability (MSl) resulting from defective DNA mismatch repair confers a better prognosis in colorectal cancer (CRC). Recently, however, data have suggested this is secondary to the effects of ploidy/ chromosomal instability (CIN). To estimate the prognostic significance of CIN for survival, data from published studies have been reviewed and pooled. Methods: Studies stratifying survival in CRC by CIN status were identified by searching PubMed and hand-searching bibliographies of identified studies. Two reviewers confirmed study eligibility and extracted data independently, and data were pooled using a fixed-effects model. The principal outcome measure was the HR for death. Results: 63 eligible studies reported outcome in 10 126 patients, 60.0% of whom had CIN+ (aneuploid/polyploid( tumours. The overall HR associated with CIN was 1.45 (95% Cl 1.35 to 1.55, p<0.001). In patients with stage Il-Ill CRCs, the HR was 1.45(95% CI 1.27 to 1.65, p<0.001). The effect was similar for progression-free survival (HR = 1.71, 95% Cl 1.51 to 1.94, p<0.001). There was no evidence of significant interstudy heterogeneity. Conclusion: CIN is associated with a worse prognosis in CRC, and should be evaluated as a prognostic marker, together with MSI status, in all clinical trials, particularly those involving adjuvant therapies.


Related Articles

  • Completion Rates of Adjuvant Chemotherapy for Colon Cancer: A Historical Perspective. Granu, Victor R.; Muggia, Franco M. // JNCI: Journal of the National Cancer Institute;5/3/2006, Vol. 98 Issue 9, p570 

    The article provides information on the impact of adjuvant chemotherapy for colon cancer. This is one of the most essential achievements in medical oncology. According to the researchers that randomized clinical trials provide with the reliable evidence of efficacy for adjuvant cancer...

  • The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer. Stinchcombe, Thomas E.; Socinski, Mark A. // Drugs;2007, Vol. 67 Issue 3, p321 

    Lung cancer is the leading cause of cancer death among men and women in the US. Surgical resection is potentially curative; however, even after complete resection many patients experience systemic recurrence and subsequently die of their disease. As a means of reducing the chances of recurrence...

  • Evidence supporting platform-switching to preserve marginal bone levels not definitive. Stafford, Gary L // Evidence-Based Dentistry;Jun2012, Vol. 13 Issue 2, p56 

    Data sourcesMEDLINE, EMBASE, The Cochrane Oral Health Group's Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL), UK National Research Register, Australian New Zealand Clinical Trials Registry (ANZCTR), Database of Abstracts of Reviews of Effectiveness (DARE), ISI...

  • Let's Bring the Trial to the Subject! Hynes, Tim // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p58 

    Focuses on the compliance and retention issues in a clinical trial. Assessment of the typical response to recruitment and retention problems; Visitation of the subject in the comfort and privacy of the home; Continuation of in-home visits performed by a qualified homecare agency; Consideration...

  • Statistics Notes: Concealing treatment allocation in randomised trials. Altman, Douglas G; Schulz, Kenneth F // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p446 

    Discusses the importance of concealing treatment allocation until a patient has entered a randomised clinical trial. Attempts to eliminate bias; How to ensure that allocation sequence will be concealed, including using external help; Difference between randomised and double blind trials.

  • Involving consumers in designing, conducting, and interpreting randomised controlled trials: questionnaire survey. Hanley, Bec; Truesdale, Ann; King, Andy; Elbourne, Diana; Chalmers, Iain // BMJ: British Medical Journal (International Edition);03/03/2001, Vol. 322 Issue 7285, p519 

    Conclusions: Consumer involvement in the design and conduct of controlled trials seems to be growing and seems to be welcomed by most researchers. Such involvement seems likely to improve the relevance to consumers of the questions addressed and the results obtained in controlled trials.

  • Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. Evans; Pocock; Lievre, Michel; Menard, Joel; Bruckert, Eric; Cogneau, Joel; Delahaye, Francois; Giral, Philippe; Leitersdorf, Eran; Luc, Gerald; Masana, Luis; Moulin, Philippe; Passa, Philippe; Pouchain, Denis; Siest, Gerard // BMJ: British Medical Journal (International Edition);03/10/2001, Vol. 322 Issue 7286, p603 

    Discusses premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. Reasons why some trials are discontinued prematurely by their sponsor for strategic reasons; How public financial and scientific participation in some trials and increasing the...

  • Fears rise over leaks of clinical trial results. Gewin, Virginia // Nature;9/8/2005, Vol. 437 Issue 7056, p191 

    Focuses on the possible leaking of clinical trial results in the U.S. Conflict-of-interest scandal facing physicians in the U.S.; Response of physicians on questions of drug performance.

  • Intention-to-treat analysis: Protecting the integrity of randomization. Mahaniah, Kiame J.; Rao, Goutham // Journal of Family Practice;Aug2004, Vol. 53 Issue 8, p644 

    Randomization is a crucial part of most clinical trials. The purpose of randomization in a trial comparing 2 groups is to ensure that the groups differ only with respect to the interventions being compared. Randomization determines not only which treatment subjects receive, but also how the...


Read the Article


Sign out of this library

Other Topics